 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment |
| Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S. Puri, Suk-Kyun Yang |
|
Intest Res. 2018;16(1):4-16. Published online January 18, 2018 DOI: https://doi.org/10.5217/ir.2018.16.1.4 |
|
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment Intestinal Research. 2018;16(1):4  Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management Intestinal Research. 2018;16(1):17 Risk of Attenuated Live Vaccines-Induced Infections in Infants of Mothers Receiving Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Gastroenterology. 2016;151(6):1250 Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment Journal of Gastroenterology and Hepatology. 2017;33(1):20-29 Risk of Serious Infection Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. ;147-151 1 LOW RISK OF LYMPHOMA IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED USING ANTI-TUMOR NECROSIS FACTOR AGENTS Gastroenterology. 2020;158(3):S3-S4 Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management Journal of Gastroenterology and Hepatology. 2017;33(1):30-36 Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy Intestinal Research. 2014;12(1):12 Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease Gastroenterology. 2017;153(4):1163-1164 Sa1119 Clinical Features of Active Tuberculosis Developed During Anti-Tumor Necrosis Factor-α Therapy in Patients With Inflammatory Bowel Diseases Gastroenterology. 2015;148(4):S-231 |
